3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

Intuitive Surgical grew its installed base of surgical robots 13% and robot-assisted surgeries 20% in Q3 2025, with roughly 75% of revenue from parts and services but trades at a high P/E of ~74. Medtronic, by contrast, trades at a P/E of 28, yields ~2.7% and has 48 consecutive years of dividend increases while developing surgical robots; Eli Lilly’s GLP-1 drugs (Mounjaro and Zepbound) drove over 50% of sales in Q3 and its P/E is ~53. Pfizer trades near a P/E of ~15, yields ~6.8% (payout ratio >100%) and strengthened its weight-loss pipeline by acquiring Metsera; Johnson & Johnson, a diversified Dividend King with a ~2.5% yield and P/E ~20, is presented as a lower-volatility long-term hold. The piece argues value-oriented Medtronic, Pfizer or diversified J&J may be preferable long-term buys versus premium-growth names Intuitive Surgical and Eli Lilly.

Analysis

Market structure: Winners are diversified device/med-tech players (MDT) and out-of-favor pharma (PFE) that can buy/replicate high-margin workflows rather than niche leaders (ISRG, LLY). ISRG and LLY benefit from secular demand (robot procedures + GLP‑1 adoption) but trade at premium multiples (P/E 74 and 53) that make them sensitive to any growth miss; JNJ sits as a defensive aggregator with 2.5% yield and lower volatility.

Risk assessment: Key tail risks include regulatory/ reimbursement shocks to GLP‑1 pricing (6–18 months), robotic device recalls/compatibility problems (0–12 months), and PFE dividend stress if payout ratio >100% persists beyond two quarters. Short-term (days–weeks) reactions will follow earnings and FDA/M&A headlines; medium (3–12 months) is adoption and supply cadence; long-term (2–5 years) is installed-base annuity capture and patent cliffs.

Trade implications: Prefer value-with-growth exposure: accumulate MDT (2–3% portfolio) and selective PFE exposure (2–4%) while using defined-loss derivative structures to express skepticism on ISRG/LLY valuations. Tactical pair ideas: long MDT vs short ISRG, long PFE vs short LLY on mean‑reversion; use 60–180 day options to time catalyst windows (earnings, FDA rulings).

Contrarian angles: Consensus underestimates integration upside from M&A (Pfizer+Metsera) and overestimates ISRG’s defensibility vs well‑capitalized rivals; conversely, market may be underpricing policy risk to GLP‑1 pricing. Historical parallels: incumbent device makers regained share after initial platform leaders peaked; unintended consequence—heavy dividend/high‑yield PFE could be a bond proxy but also a dividend cut risk if cash flow weakens.

Key Decisions for Investors

• Establish a 2–3% long position in MDT within the next 2 weeks for a 12–24 month hold; scale in on any pullback of 8%+ or if MDT P/E falls to ≤24; set a partial trim target if MDT outperforms ISRG by +20% or MDT P/E expands to ≥35.
• Initiate a 2–4% position in PFE via cash‑secured puts 8–12% OTM with 60–90 day expiries (collect premium and enable ~6–7% yield if assigned); close or cut exposure if payout ratio remains >100% for two consecutive quarters or if FDA/M&A integration guidance turns negative.
• Open a bearish 0.5–1% exposure to ISRG via a 3‑month put spread (buy 6% OTM put, sell 15% OTM) to limit max loss while betting on valuation mean reversion if YoY robot procedure growth decelerates below 10% over the next two quarters.
• Allocate 2–3% to JNJ as a defensive core holding for 18+ months and write 3‑month covered calls 10% OTM to enhance yield; roll if call premium <1% or if JNJ dividend cut risk exceeds 10% probability based on cash flow trends.